AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
Other Receivables
AstraZeneca PLC
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AstraZeneca PLC
LSE:AZN
|
Other Receivables
$1.9B
|
CAGR 3-Years
41%
|
CAGR 5-Years
46%
|
CAGR 10-Years
19%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Other Receivables
£489m
|
CAGR 3-Years
0%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Other Receivables
$5.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Other Receivables
$34m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Other Receivables
$24m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
0%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Other Receivables
£0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
AstraZeneca PLC
Glance View
AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.
See Also
What is AstraZeneca PLC's Other Receivables?
Other Receivables
1.9B
USD
Based on the financial report for Dec 31, 2024, AstraZeneca PLC's Other Receivables amounts to 1.9B USD.
What is AstraZeneca PLC's Other Receivables growth rate?
Other Receivables CAGR 10Y
19%
Over the last year, the Other Receivables growth was 30%. The average annual Other Receivables growth rates for AstraZeneca PLC have been 41% over the past three years , 46% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet